- Home
- CDTG vs CGTX Comparison
CDTG vs CGTX Comparison
Compare CDTG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- CGTX
- Stock Information
- Founded
- CDTG 2012
- CGTX 2007
- Country
- CDTG China
- CGTX United States
- Employees
- CDTG N/A
- CGTX N/A
- Industry
- CDTG
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- CGTX Health Care
- Exchange
- CDTG NYSE
- CGTX Nasdaq
- Market Cap
- CDTG 24.5M
- CGTX 26.8M
- IPO Year
- CDTG 2024
- CGTX 2021
- Fundamental
- Price
- CDTG $2.45
- CGTX $0.37
- Analyst Decision
- CDTG
- CGTX Strong Buy
- Analyst Count
- CDTG 0
- CGTX 5
- Target Price
- CDTG N/A
- CGTX $7.13
- AVG Volume (30 Days)
- CDTG 362.2K
- CGTX 597.0K
- Earning Date
- CDTG 04-29-2025
- CGTX 05-06-2025
- Dividend Yield
- CDTG N/A
- CGTX N/A
- EPS Growth
- CDTG N/A
- CGTX N/A
- EPS
- CDTG 0.72
- CGTX N/A
- Revenue
- CDTG $31,432,824.00
- CGTX N/A
- Revenue This Year
- CDTG N/A
- CGTX N/A
- Revenue Next Year
- CDTG N/A
- CGTX N/A
- P/E Ratio
- CDTG $3.40
- CGTX N/A
- Revenue Growth
- CDTG N/A
- CGTX N/A
- 52 Week Low
- CDTG $1.16
- CGTX $0.31
- 52 Week High
- CDTG $4.64
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- CGTX 43.09
- Support Level
- CDTG N/A
- CGTX $0.31
- Resistance Level
- CDTG N/A
- CGTX $0.41
- Average True Range (ATR)
- CDTG 0.00
- CGTX 0.04
- MACD
- CDTG 0.00
- CGTX 0.01
- Stochastic Oscillator
- CDTG 0.00
- CGTX 51.54
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.